Abstract NK cell activity is tuned by a balance of activating and inhibitory signals transmitted via their respective receptors, including killer immunoglobulin-like receptors (KIRs). The impact of NK cells on graft-versus-leukemia following hematopoietic stem cell transplantation (HSCT) is well established. These effects sometimes lead to GvHD. The link between KIR/HLA interaction and GvHD remains unclear. Herein, we studied the impact of the KIR/HLA interaction on HSCT outcomes in a longitudinal follow-up study of a highly consanguineous HLA-matched related cohort. Peripheral blood DNA was collected from HSCT donor-recipient pairs (n = 87), including 41 AML pairs. KIR and HLA were genotyped and significant results were only measured when matching KIR (donor) with HLA (recipients). GvHD was observed in 47% of patients. KIR2DL1_C2 and 2DS2_C1 (P = 0.02 and 0.04, respectively) matching was associated with an increased incidence of acute GvHD in AML donor-recipient pairs. The rate of chronic GvHD also rose in AML patients who were matched for KIR2DS1_C2 (P = 0.004) and had either KIR2DL2 or KIR2DS2 (P = 0.03). In conclusion, matching of KIR2DL1, 2DS1, and 2DS2 in donors with their HLA-C ligands in recipients is associated with increased GvHD, and holds potential for selection of HSCT donors.
Introduction
Acute myeloid leukemia (AML) is the most common leukemia affecting adults, and its incidence increases with age. According to the latest Cancer Incidence Report in Saudi Arabia, 684 new cases of adult leukemia per 100,000 people were documented in 2013. This accounts for 5.9% of all new adult cancers [1] . Leukemia is considered the third and sixth most common malignancy in Saudi males and females, respectively. In 2013, 82 of 684 newly reported leukemia patients (12%) were patients with AML [1] .
AML is considered an age-related malignancy with a mean age of 70 years at diagnosis [1] . The established treatment regime for high-risk AML consists of chemotherapy followed by allogeneic hematopoietic stem cell transplantation (HSCT) [2] [3] [4] . The outcome of HSCT is affected by the optimal matching of HLAs between the patient and the donor [5] . Success of HSCT primarily depends on the graft-versus-leukemia (GvL) effect, which plays a major role in the eradication of residual leukemic cells [6] . The key players in GvL are the T lymphocytes and natural killer (NK) cells of the donor-derived alloreactive These authors contributed equally: Ameera Gaafar, Atia Sheereen.
immune cells [7] [8] [9] [10] . NK cell reactivity is largely tuned by a balance of activating and inhibitory signals transmitted via their respective receptors, including the highly polymorphic killer immunoglobulin-like receptors (KIRs) [9, 11] . Inhibitory KIRs recognize HLA class I molecules (group 1 and group 2 HLA-C alleles) and Bw4 alleles [12] . KIR and HLA genes are situated on chromosomes 19 and 6, respectively. This means that KIR and HLA genes are inherited independently of each other, and KIR mismatching can occur in HLA-matched sibling pairs. KIR genes are arranged in two major haplotypes, A and B, which mainly differ in the number of activating KIRs they comprise [13] [14] [15] [16] . Of all hematologic malignancies treated with HCST, AML is most sensitive to NK reactivity. The first evidence of the role of KIR ligand mismatch in HSCT was reported in AML recipients [10] . Moreover, the impact of matching donor KIRs with their respective ligands in the patient was shown to be transplant protocol-dependent, with the extent of donor Tcell depletion being an important variable [17] . Furthermore, donors with KIR B-haplotypes with defining genes 2DS1, 2DS2, and 2DS3 have a reduced incidence of relapse, especially in patients with AML [18] . However, these results remain controversial, and contradictory results have been reported [19, 20] . These contradictions may be attributed to NK alloreactivity between donor and patient, linked to both KIR and KIR-ligand mismatching, or to differences in clinical status, treatment protocols, and genetic background. Additionally, the frequencies of HLA ligands in patients have been reported to affect HSCT outcomes [21] .
Previous reports have focused on the role of KIR genes in haploidentical settings in multi-center clinics and in patients from diverse genetic backgrounds [22, 18] . To date, few data have been analyzed concerning the role of KIR in HSCT outcomes, especially GvHD, in a population with high consanguinity and little genetic variability, such as the Saudi Arabian population [23] . Therefore, we sought to investigate the roles of donor KIR and recipient HLA repertoires, and their interaction, in HSCT outcomes in a homogeneous population with high consanguinity and low genetic variability treated in a single center.
Materials and methods

Patients and transplant protocols
This study was approved by the ethics committee of the King Faisal Specialist Hospital and Research Center (KFSHRC), Saudi Arabia. All samples were collected after obtaining written informed consent from patients and donors and were approved for use by the King Faisal Specialist Hospital and Research Centre Review Board. In total, 87 related HSCT recipient-donor pairs were screened.
All patients underwent allogeneic transplantation after having undergone either myeloablative (MA) or reduced intensity and myeloablative regimens (Table 1a) . The MA conditioning consisted of BUSULFAN/cyclophosphamide (35%), cyclophosphamide and total body irradiation (49%), and others (16%). All patients received a T-cell-repleted graft. The recipients included patients with acute lymphoid leukemia (n = 38), acute myeloid leukemia (n = 41), chronic lymphoid leukemia (n = 1), chronic myeloid leukemia (n = 5), and myelodysplastic syndrome (n = 2). Relapse was detected by appropriate laboratory analysis of blood and/or bone marrow. Some patients received a donor lymphocyte infusion to treat relapse. Granulocytes were isolated by density-gradient centrifugation of heparinized blood using Ficoll-Hypaque separation (Amersham Biosciences, New Jersey, USA). GvHD prophylaxis consisted of cyclosporine methotrexate. Methylprednisolone was used as a first-line therapy for acute GvHD at an initial dose of 0.5-2.0 mg/kg. All patients were of Saudi ethnicity and were transplanted with cells from an immediate sibling.
HLA typing
HLA class I (HLA-A*, -B*, and -Cw*) and II (DRB1*, DQB1*, and DPB1*) typing was performed using 
KIR genotyping
All patients and donors were KIR-genotyped as described previously [23] . The missing KIR ligand algorithm was calculated as described previously [23] . The impact of haplotype B (defined by the presence of one of the genes KIR2DL5A, 2DS1, 3DS1, 2DS2, 2DS3, or 2DS5) was also assessed in the donors [27] .
Statistical analysis
Categorical variables were summarized as frequency counts, and percentages and continuous variables were summarized as medians and ranges, respectively. Four outcomes were assessed: overall survival (OS), defined as time to death from any cause; disease-free survival (DFS), defined as time to relapse or death; systemic acute graftversus-host disease (aGvHD), defined as time to the development of grade II-IV aGvHD, and in which death without aGvHD was considered a competing event; and chronic GvHD (cGvHD), defined as time to the development of cGvHD, and in which death without evidence of cGvHD was considered a competing event.
The probabilities of OS and DFS were calculated using the Kaplan-Meier method, and comparisons were made using the log-rank test. The probability of relapse, aGvHD, and cGvHD was calculated using the cumulative incidence function, accounting for the competing events, and compared using the Gray test. P < 0.05 was considered statistically significant. Variables with P < 0.1 were included in a multivariate Cox regression proportional hazard model after checking for proportionality assumption.
Results
Donor and patient characteristics
The demographics and characteristics of the 87 HSCT patient-donor pairs are summarized in Table 1a , and those of the 41 AML patient-donor pairs in Table 1b . The median time of follow-up was 2 years (0.25-5 years).
Influence of individual AML donor KIR genes based on patients' GvHD status
In general, the frequencies of KIR genes were comparable in the HSCT patients when grouped according to their primary illness. However, 2DS3 was an exception, and tended to be associated with AML (P < 0.05). Two-thirds of patients with AML lacked 2DS3 (27/41, 66%) (Supplementary Figure S1) . Additionally, the frequencies of the selected inhibitory and activating KIR genes (2DL2, 2DL5B, 2DS1, and 2DS2) were higher in donors whose AML recipients developed aGvHD (20/41) than in donors whose recipients did not develop aGvHD (21/41). However, this difference only reached borderline statistical significance for KIR2DL2 (P = 0.05) and 2DS2 (P = 0.05; Fig. 1a) . A different pattern was observed when comparing AML donors whose recipients developed cGvHD and AML donors whose recipients did not develop cGvHD (Supplementary Figure. S2 ).
In this cohort, there was a significant association between the absence of 2DL2 or 2DS2 and the probability of developing cGvHD (P = 0.03; Fig. 2b ).
Effect of KIR/HLA matching on the outcome of HSCT Although KIR and HLA were genotyped in the entire cohort, significant results were only measured when Tables 2 and  3) . A statistically significant association was identified between the incidence of aGvHD in the HSCT group and the matching of inhibitory KIR 2DL1 and HLA-C2 (2DL1_C2) (P = 0.02; Fig. 3a) . Upon clustering based on the primary illness of recipients, a significant association was observed only in AML donor-recipient pairs (2DL1_C2) (P = 0.02; Fig. 3b ). Furthermore, higher aGvHD was observed in patients with AML who were 2DS2_C1-matched in the donor-recipient pair than nonmatched (P = 0.04, Fig. 3c ). A significant increase in cGvHD was also observed in patients with AML when matching donor KIR2DS1 with recipient HLA-C2 (2DS1_C2) (P = 0.004, Fig. 4) . Moreover, the presence of 2DL2/2DS2 in donors was significantly associated with a high incidence of cGvHD in AML recipients (P = 0.03; Fig. 2b ). Differences in DFS and OS were found to be insignificant for all KIR genes in donors when matched with HLA-C in the total HSCT set and in AML recipients. However, HLA-C genotypes were significantly associated with aGvHD in HSCT patients (P = 0.02; Fig. 5 ). Multivariate analysis revealed that 2DS1_C2 matching and the presence of 2DL2 or 2DS2 were significantly associated with cGvHD (P = 0.01 and 0.04, respectively; Table 4 ).
Impact of different HLA genotypes on HSCT outcome: aGvHD
We examined the prevalence of HLA-Bw4 and HLA-C1/C2 homozygotes and heterozygotes among recipients and their association with different HSCT outcomes. The HLA-C genotype was significantly associated with the probability of developing aGvHD in the HSCT recipient data set, but the correlation did not reach significance in patients with AML (P = 0.02, 0.07 respectively; Fig. 5 ). Furthermore, HLA-C1/C1 homozygosity was associated with GVHD in patients with AML, but the difference only reached statistical significance in patients with aGvHD (P = 0.02; Fig. 1a ). All patients with HLA-C1/C1 who developed aGvHD eventually died (Fig. S3) . Matching of 3DL1/HLABw4 was only associated with the incidence of cGvHD and overall survival in patients with AML (P = 0.129; Figure S4 ). Generally, we found that HLA-C genotypes influenced the manifestation of aGvHD in HSCT patients who developed aGvHD (P = 0.02). A favorable outcome and increased overall survival rates were associated with HLA-C2 homozygosity, whereas increased mortality was associated with HLA-C1 homozygosity. Overall 75% of the AML patients acquired GvHD, and most of the death occurred from relapse (60%); 15% of deaths were caused by aGvHD, 30% by cGvHD, and 5% from other causes including infections (data not shown).
The study findings are summarized in Fig. 6 .
Discussion
We assessed the influence of KIR/HLA interactions on the outcome of HSCT-related patient-donor pairs in a homogeneous cohort from the Saudi Arabian population. We 2DL1  2DL2  2DL3  2DL5A  2DL5B  2DS1  2DS2  2DS3  2DS4  1D  2DS5  3DL1  3DS1  2DP1  C1H  C2H  C1C2  AA1 or 2DS2 in AML donor-recipient pairs. cGvHD incidence was higher in patients with KIR2DL2/2DS2 = 1, and significance was achieved in patients with AML (P < 0.05)
anticipated that the impact of KIR/HLA interactions would be more noticeable in a cohort with lower genetic variability and high consanguinity. Consistent with previous reports, we observed a highly significant correlation with KIR/HLA in the AML cohorts when we grouped donor/recipient pairs according to primary illness [10, 18] . We found that matching KIR in the donors with HLA in the recipients was highly associated with GvHD in both the HSCT and AML cohorts, but the association was stronger in the AML cohort. This effect was particularly noticeable when matching the inhibitory 2DL1 and the activating 2DS1 of donors with their HLA-C2 ligand in recipients, and the activating 2DS2 with its HLA-C1 ligand. HLA/KIR associations were more obvious when donors were analyzed according to the clinical outcome of their AML recipients following transplantation. AML is the most sensitive neoplasm to NK cell lysis, and the first evidence for a role of KIR/HLA mismatch in HSCT outcome was reported in AML haploidentical transplant patients [28, 10] . These discoveries led to retrospective immunogenetics analyses in HLA-mismatched transplant settings, where alloreactivity caused by KIR-ligand (KIR/HLA) mismatch was expected to occur [29, 20] . Here, increased frequencies of KIR2DL2 and 2DS2 were observed in the donors of patients with AML with aGvHD and/or cGvHD compared to those without aGvHD or cGvHD complications. Apparently, strong inhibition by 2DL1-C2 and strong activation by 2DS1-C2 negate the effect mediated by the interaction of the HLA-C1 ligand with KIR2DL2, 2DL3, and 2DS2 in GvHD patients. This was corroborated by the observation of increased 2DS1-C2 and 2DS2-C1 matching in all HSCT pairs, which was more amplified in the AML pairs. This matching induced excessive activation of NK cells and exaggerated the immune responses, eventually leading to clinical symptoms of GvHD. This might explain why most patients with aGvHD have the C1C2 genotype, indicating a greater amount of interaction with KIR receptors, if present in their donors. Moreover, this speculation is supported by the fact that in this study, all patients with AML who developed aGvHD, and later died, were C1C1 homozygotes, and the majority had been matched for 2DL1-C1 (data not shown). Indeed, the majority of patients with AML with aGvHD in this study had the HLA-C1C2 or C2C2 genotypes. Whether this association occurred by chance or whether patients with HLA-C2 genotypes are more susceptible to GvHD requires further investigation. Notably, OS was influenced by the absence of 2DL2 and/or 2DS2 in the donors and by the presence of relapse or GvHD in the recipients. Increased mortality was observed in patients with AML who suffered from disease relapse and/ or GvHD and lacked certain KIR haplotypes (e.g., Bx genes, 2DL2 and 2DS2). The influence of the B-KIR haplotype on HSCT outcome has been noted in many reports, and its presence has been linked with favorable outcomes [18] . Effect of KIR/HLA matching and mismatching on the outcome among recipients of all the 87 related HSCT donors. Univariate analysis revealed a significant association (P < 0.05) in the incidence of aGvHD among the 87 HSCTs. Marginal effect was seen on OS and DFS, no effect was observed on cGvHD, and the only marginal effect was with 2DL2/2DS2
The HLA-C genotype was found to significantly influence OS. Better survival was observed in HSCT recipients homozygous for HLA-C2, and poorer survival was noted in recipients with the C1C1 and C1C2 genotypes. The influence of the HLA-C genotype on OS has been reported previously [30] , and its effects are amplified by interaction with the KIR genes. This finding indicates that the high mortality observed in patients with HLA-C1 homozygosity and C1C2 heterozygosity increases in the presence of donor KIR2DL1 and 2DS1. Therefore, different KIR genes and KIR/HLA-C interactions are involved in the development of aGvHD, cGvHD, and death. These results provide further evidence that successful HSCT involves the cooperation of many genes.
Due to their locations on different chromosomes, KIR and HLA interactions also independently influence the outcome of HLA-matched transplantation [31, 32, 18] . The effect of individual KIRs on transplantation outcome is often difficult to determine due to extensive linkage disequilibrium at the KIR locus [33] . Despite the relatively small cohort explored in this study, our data revealed associations between individual KIR and HLA genes and the incidence of aGvHD and cGvHD. This could be attributed to the homogeneity of the Saudi cohort, as the majority was matched for HLA (HLA-identical sibling transplants), as well as the unified treatment management applied. However, the patients were not matched for HLA-C, which made it easy to study the effect of HLA-C and KIR interactions. The ligands for several KIRs are not known, which makes it difficult to speculate on the underlying mechanisms. The specific ligands of KIR2DS3 and 3DS1 have not been reported, but they have been identified as KIR genes affecting the clinical outcome in HLAidentical HSCT [29, 4] . Moreover, KIR2DS3 has a protective effect against chronic GVHD [34] . Schellekens et al. [4, 35] described a positive correlation between relapse in patients with KIR2DS3 and the absence of KIR2DS3 in unrelated donors from whom the patients received grafts.
Our results provide constructive data for donor-recipient status based on KIR-ligand matching in HSCT in a Saudi population. However, it is difficult to formulate definitive guidelines for donor selection across all populations, as many KIR ligands remain unknown. A limitation of this study was the relatively small sample size; however, strong associations were observed between KIR/HLA and GvHD. Thus, KIR/HLA matching should be explored in a larger HSCT cohort to validate and strengthen the results obtained here.
In summary, our study demonstrated that the outcomes of HLA-identical sibling transplants were affected by the combination of KIRs and KIR-ligand matching, especially in patients with AML. Additionally, the HLA repertoire of the recipient crucially affects the outcome, including GvHD onset and OS of all HSCT recipients. Therefore, we anticipate that in hospitals where selection of donors and Effect of KIR/HLA matching and mismatching on the outcome among AML recipients of related donors. Univariate analysis revealed a significant association (P < 0.05) in the incidence of both acute and chronic GvHD among AML recipients. No effect was seen in OS or DFS Multivariate Cox proportional hazards regression analysis revealed a significant association between cGvHD (P < 0.05) among AML recipients of related donors and the presence of KIR2DL2/2DS2 and KIR2DS1_C2 matching genotyping of KIR/HLA before HSCT are feasible, recipients with HLA-C2 when donors carry KIR2DL1 or 2DS1 and recipients with HLA-C1 when donors carry 2DS2 should be closely monitored, and an additional prophylactic regime can be introduced to prevent the adverse complications of GvHD and to improve the HSCT outcome. Finally, prospective studies on a global scale are warranted to elucidate the mechanisms involved and to prove the association across different racial groups and populations. 
